If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 11 - 20 of 289
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors
Objective
The study is researching an investigational drug called REGN7075 by itself and in combination
with cemiplimab with or without chemotherapy.
with cemiplimab with or without chemotherapy.
Protocol No
REGENERON-R7075-ONC-2009
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib vs Physicians Choice in Subjects with FGFR-Altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma
Objective
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (FIRST-308)
Protocol No
TRANSTHERA-TT420C2308
Categories
A Randomized, Masked, Placebo Controlled, Phase II Trial of Concurrent Chemoradiation with BMX-001 in Patients with Head and Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation
Objective
Study of BMX-001 radioprotector with chemoradiation therapy for H/N cancer patients
Protocol No
NRG-CC013
Categories
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Objective
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma?
We are doing this study to find out if this approach is better or worse than the usual approach to treating low tumor burden follicular lymphoma.
We are doing this study to find out if this approach is better or worse than the usual approach to treating low tumor burden follicular lymphoma.
Protocol No
SWOG-S2308
Categories
A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-Based Treatment Combinations or MK-5684 Alone in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Objective
Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Protocol No
MERCK-MK-5684-01A
Categories
Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Complications
Objective
CVN424 in Parkinson's Disease Participants With Motor Complications
Protocol No
NEURO-CEREVANCE-CVN424-301
Establishing an AI-based Foundation for Remote Automated Speech and Language Therapy in Aphasia
Objective
PIC NAME AI
Protocol No
NEURO-IIT-ANDERSON-PICNAMEAI
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND)
Objective
Felzartamab for the Treatment of Late Antibody-Mediated Rejection in Kidney Transplant Recipients
Protocol No
SURG-BIOGEN-TRANSCEND
Categories
The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (the "EMAGINE 2.0" Study)
Objective
Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment - EMAGINE 2.0
Protocol No
PMR-BRAINQ-EMAGINE-2
Categories
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients A
Objective
Testing the effects of novel therapeutics for newly diagnosed, untreated patients with acute myeloid leukemia
Protocol No
SWOG-MM1YA-S01
Categories